Cambridge Nutritional Science’s (CNS) has reported FY25 full year results to end-March, in-line with the May 2025 trading update. While sales were slightly softer, we note that CNS continued to deliver gross margin improvements during the period, up 346bps to 65.3% from 61.9%, leading the group to post FY25 Adj. EBITDA of £0.4m (FY24: £0.2m). CNS has continued to invest in operational excellence initiatives in FY25 to deliver further efficiencies going forward while also strengthening its commer ....
